Latest Headlines

Latest Headlines

Pharma shares sink as U.S. threatens tax-inversion crackdown

U.S. drugmakers have embraced the tax inversion strategy with open arms as of late, buying up foreign companies right and left and hauling overseas to take advantage of their lower rates. But U.S. officials are looking to stop them in their tracks--an intent that has some pharma investors worried.

St. Jude seals the deal with NeuroTherm to gain ground in neuromodulation

St. Jude Medical finalized its acquisition of interventional pain management therapy manufacturer NeuroTherm, gaining ground in a highly competitive neuromodulation market and expanding its chronic pain portfolio.

Pfizer needs to ink a big deal, pronto. GSK or Actavis, maybe?

A couple of things happened this past week to set off new chatter about a Pfizer megadeal. First, GlaxoSmithKline posted disappointing earnings and cut its full-year forecast, sending its stock into the dumpster--and its market cap tumbling. Then, Berenberg analysts issued an investor note extolling the potential virtues of a Pfizer-GlaxoSmithKline combo. Let the speculation continue.

In a surprise twist, Treasury takes aim at Big Pharma's tax inversion deals

Tax inversions are one of the hottest trends in biopharma. But with lawmakers unable so far to reach a deal on new legislation, the Obama administration is signaling that it wants to put a stop to it--now. And it's looking for a way to go it alone, leaving lawmakers on the sidelines.

UCB hops on pharma's spinoff wagon with potential $2B sale of generics business

Shedding noncore assets is the trend du jour in Big Pharma, and now another company may be jumping on the bandwagon. Belgium's UCB is reportedly looking into a sale of Kremers Urban Pharmaceuticals, its Princeton, NJ-based generics unit.

Ackman's crusade for Valeant-Allergan combo gets a key nod from proxy advisers

Bill Ackman hasn't rounded up enough support to call the special meeting of Allergan shareholders that's crucial to Valeant's buyout bid. But now, he's got a proxy advisory firm to back his cause.

MGC Diagnostics completes Belgian M&A deal with an eye on globalization

Minnesota's MGC Diagnostics has completed its acquisition of a promising Belgian competitor, putting its plan for global expansion in place less than a month after the M&A deal was first announced.

Roche's pRED buys out Santaris in $450M RNA acquisition

Roche's European-based R&D arm pRED has closed a deal to buy Denmark's Santaris Pharma, paying $250 million upfront with another $200 million up for grabs in potential milestones if the research pays off. The deal marks a big increase in Roche's bet on RNA-targeting drugs, a research sector it exited with great fanfare several years ago as experts debated the potential for the field.

Enumeral banks $21.5M for immuno-oncology R&D

Biotech startup Enumeral Biomedical has pulled off a deal that gives it $21.5 million in financing and access to public markets, paving the way for early-stage work on some cancer immunotherapies.

PE-backed Tecomet to buy Symmetry Medical unit for $450M

When Genstar Capital acquired orthopedic implant company Tecomet in December, the private equity firm aimed to build up the company's growth both organically and through acquisitions. It's making good on the latter strategy with the newly announced purchase of the equipment business of Symmetry Medical for $450 million.